European Leukemia Trial Registry
Trial: ETAL-3-ASAP

More Details
Title Phase III Studie zu Cytarabine und Mitoxantrone als Induktionstherapie vor SZT bei AML
Scientific Title Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML
Short Title ETAL-3-ASAP
Trialgroup SAL
Type of Trial multicentric, randomized, double-group
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age 18 - 75 years
Status Active
Start of Recruitment 01.11.2015
Leader Schetelig, Prof. Dr. med., Johannes
Contactperson

Administrative needs
Noack, Katja
Email: Noack@dkms.de

Shortprotocol Shortprotocol
created 04.01.2016 Zenawit Krüger
changed 12.10.2016 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org